Fig. 6: Survival prediction of HER2 + mBC patients by the 4-lncRNA signature in chemotherapy-only patients. | Cell Death Discovery

Fig. 6: Survival prediction of HER2 + mBC patients by the 4-lncRNA signature in chemotherapy-only patients.

From: A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study

Fig. 6

A, B Kaplan‒Meier survival analysis of patients in the chemotherapy cohort and two validation cohorts according to the 4-lncRNA signature and T-DM1 therapy. C–F The therapeutic advantage was evaluated via Kaplan‒Meier analysis. Patients were segregated according to treatment options into high- and low-score groups. p values were calculated with the two-sided log-rank test.

Back to article page